Consensus Regeneron Pharmaceuticals, Inc. Sao Paulo

Stocks

REGN34

BRREGNBDR005

Pharmaceuticals

Market Closed - Sao Paulo 10:07:30 2026-09-11 EDT			5-day change	1st Jan Change
66.50 ^BRL	-1.76%		-5.94%	-6.22%

09-10	Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says	MT
09-09	Regeneron Pharmaceuticals, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 08:45 AM

f26c4.RDuFLnsRbd-AX6Wj4ZiSyGBTcecW-HM8oMkZ0dZ7s_U.EA-zeigpMr3yKMDmhNTchzAyA59yqkVq65l35uIT380cb8tEP3o-7e8LlQ~ef977c5d703486b16e042612d5a34b68

Analysts' recommendations: Regeneron Pharmaceuticals, Inc.

09-09	BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $920 From $800, Keeps Outperform Rating	MT
09-01	Regeneron Seen Weighing Expanded Sanofi Deal, RBC Says	MT
08-17	Leerink Partners Adjusts PT on Regeneron Pharmaceuticals to $824 From $641, Maintains Market Perform Rating	MT
08-14	Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating	MT
07-31	Regeneron Pharmaceuticals' Robust Q2 Sales Amid Limited Spend Increases to Help Ramp H2 Margins, RBC Says	MT
07-31	RBC Raises Price Target on Regeneron Pharmaceuticals to $737 From $696, Keeps Sector Perform Rating	MT
07-31	Baird Adjusts Price Target on Regeneron Pharmaceuticals to $761 From $742, Maintains Neutral Rating	MT
07-31	Wells Fargo Adjusts PT on Regeneron Pharmaceuticals to $750 From $700, Maintains Equalweight Rating	MT
07-31	Morgan Stanley Adjusts PT on Regeneron Pharmaceuticals to $758 From $730, Keeps Equalweight Rating	MT
07-31	JPMorgan Adjusts PrT on Regeneron Pharmaceuticals to $900 From $850, Maintains Overweight Rating	MT
07-31	Cantor Fitzgerald Adjusts PT on Regeneron Pharmaceuticals to $795 From $750, Maintains Overweight Rating	MT
07-31	Raymond James Adjusts PT on Regeneron Pharmaceuticals to $911 From $902, Keeps Outperform Rating	MT
07-31	BMO Capital Adjusts PT on Regeneron Pharmaceuticals to $800 From $730, Maintains Outperform Rating	MT
07-31	Evercore ISI Adjusts PT on Regeneron Pharmaceuticals to $850 From $825, Maintains Outperform Rating	MT
07-31	Goldman Sachs Adjusts PT on Regeneron Pharmaceuticals to $972 From $965, Maintains Buy Rating	MT
07-30	The Fed Gets a Better Inflation Number
07-21	Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $750 From $785	MT
07-21	Guggenheim Adjusts PT on Regeneron Pharmaceuticals to $1,000 From $995, Maintains Buy Rating	MT
07-20	Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $965 From $968, Maintains Buy Rating	MT
07-09	Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $854 From $855	MT
07-08	Morgan Stanley Adjusts Price Target Regeneron Pharmaceuticals to $730 From $788, Maintains Equalweight Rating	MT
07-07	Truist Securities Adjusts Regeneron Pharmaceuticals Price Target to $769 From $778	MT
07-07	RBC Capital Adjusts Regeneron Pharmaceuticals Price Target to $696 From $707, Maintains Sector Perform Rating	MT
07-06	HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $800 From $990	MT
05-18	Canaccord Genuity Cuts Regeneron Pharmaceuticals Price Target to $875 From $1,057, Maintains Buy Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	REGENERON PHARMACEUTICALS, INC.					+8.68%
	CSL LIMITED					+2.83%
	MODERNA, INC.					-16.96%
	SAMSUNG BIOLOGICS CO.,LTD.					+39.05%
	UCB					+38.62%
	BIOGEN INC.					+9.23%
	INCYTE CORPORATION					+5.16%
	INNOVENT BIOLOGICS, INC.					+37.46%
	SWEDISH ORPHAN BIOVITRUM AB					+14.26%
	Average					+15.37%
	Weighted average by Cap.					+13.02%